Technical Analysis for PRVB - Provention Bio, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
2.44 | 2.52% | 0.06 |
PRVB closed up 2.52 percent on Monday, December 17, 2018, on 77 percent of normal volume. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | N/A | Down | Down |
| See historical PRVB trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Dec 17 | Hammer Candlestick | Bullish | 0.00% |
| Dec 17 | Outside Day | Range Expansion | 0.00% |
| Dec 14 | Narrow Range Bar | Range Contraction | 2.52% |
| Dec 14 | NR7 | Range Contraction | 2.52% |
| Dec 13 | Fell Below 20 DMA | Bearish | 2.95% |
| Dec 12 | 1,2,3 Retracement Bearish | Bearish Swing Setup | -8.44% |
| Dec 12 | Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -8.44% |
| Dec 12 | Crossed Above 20 DMA | Bullish | -8.44% |
| Dec 12 | Wide Bands | Range Expansion | -8.44% |
| Dec 11 | 20 DMA Resistance | Bearish | -4.31% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2018-11-08
Provention Bio, Inc. is a clinical-stage biopharmaceutical company that develops therapeutics targeting immune-mediated diseases. The Company aims at developing therapies for disease that include type one diabetes (T1D), Crohn’s disease, ulcerative colitis, lupus and other viral diseases. The Company’s principal product candidates include PRV-031, PRV-6527, PRV-300, PRV-3279, and PRV-0101.PRV-031 is a product candidate in its Phase III clinical trial that is developed for the interception of T1D. PRV-6527 is an oral CSF-1R inhibitor for the treatment of Crohn’s disease. PRV-300 is developed for the treatment of ulcerative colitis. PRV-3279 is developed to treat lupus disease. PRV-101 is a multivalent coxsackie virus (CVB) vaccine for the prevention of acute CVB and the prevention of the onset of T1D.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more PRVB news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 8.0 |
| 52 Week Low | 2.02 |
| Average Volume | 42,418 |
| 200-Day Moving Average | 0.0 |
| 50-Day Moving Average | 2.9599 |
| 20-Day Moving Average | 2.5383 |
| 10-Day Moving Average | 2.4885 |
| Average True Range | 0.2729 |
| ADX | 45.75 |
| +DI | 9.3163 |
| -DI | 27.6661 |
| Chandelier Exit (Long, 3 ATRs ) | 2.3313 |
| Chandelier Exit (Short, 3 ATRs ) | 2.8387 |
| Upper Bollinger Band | 2.8628 |
| Lower Bollinger Band | 2.2138 |
| Percent B (%b) | 0.35 |
| BandWidth | 25.568294 |
| MACD Line | -0.1629 |
| MACD Signal Line | -0.1845 |
| MACD Histogram | 0.0216 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.71 | ||||
| Resistance 3 (R3) | 2.68 | 2.56 | 2.67 | ||
| Resistance 2 (R2) | 2.56 | 2.49 | 2.58 | 2.65 | |
| Resistance 1 (R1) | 2.50 | 2.45 | 2.53 | 2.53 | 2.63 |
| Pivot Point | 2.38 | 2.38 | 2.40 | 2.40 | 2.38 |
| Support 1 (S1) | 2.32 | 2.31 | 2.35 | 2.35 | 2.25 |
| Support 2 (S2) | 2.20 | 2.27 | 2.22 | 2.23 | |
| Support 3 (S3) | 2.14 | 2.20 | 2.22 | ||
| Support 4 (S4) | 2.17 |
